Cargando…

Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as “Lung Squamous Cell Carcinoma”: A Case Report and Review of the Literature

The rarity and complexity of histology lead to the low diagnosis rate and high misdiagnosis rate of combined small cell lung cancer (C-SCLC). Nowadays, C-SCLC has no commonly recommended therapeutic regimen, mainly conforming to SCLC treatment. Here, we report a patient initially diagnosed as IIIA “...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Yong, Li, Qijun, Li, Da, Fang, Yong, Wang, Chongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924069/ https://www.ncbi.nlm.nih.gov/pubmed/35309345 http://dx.doi.org/10.3389/fimmu.2022.831698

Ejemplares similares

Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature
por: Leitinger, Markus, et al.
Publicado: (2018)

Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
por: Li, Na, et al.
Publicado: (2021)

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2023)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

A Case of Metastatic Rectal Squamous Cell Carcinoma Initially Diagnosed as Lung Cancer
por: Win, Aung Zaw, et al.
Publicado: (2015)

Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
por: Hui, Zhenzhen, et al.
Publicado: (2015)

Sex difference in the expression of PD-1 of non-small cell lung cancer
por: Gu, Yong, et al.
Publicado: (2022)

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma
por: Li, Qijun, et al.
Publicado: (2021)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival
por: Chen, Rui-Lian, et al.
Publicado: (2020)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Immune Cell Composition in Human Non-small Cell Lung Cancer
por: Stankovic, Branislava, et al.
Publicado: (2019)

Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients
por: Yang, Yong, et al.
Publicado: (2022)

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
por: Xiong, Anning, et al.
Publicado: (2023)

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review
por: Dong, Yong, et al.
Publicado: (2021)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer
por: Gunther, Sophie, et al.
Publicado: (2015)

Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c(+) Conventional Dendritic Cell Subsets Mediated by CD103 and CD205
por: Lu, Yong, et al.
Publicado: (2019)

Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer
por: Zhao, Ying, et al.
Publicado: (2022)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
por: Ho, Hsiang-Ling, et al.
Publicado: (2019)

Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
por: Chen, Shanshan, et al.
Publicado: (2023)

Deep immune B and plasma cell repertoire in non-small cell lung cancer
por: Patel, Akshay J., et al.
Publicado: (2023)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
por: Qin, Jian, et al.
Publicado: (2023)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index
por: Wu, Rihan, et al.
Publicado: (2023)

LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma
por: Su, Yongcheng, et al.
Publicado: (2022)

Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence
por: Peng, Haoxin, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma
por: Zhou, Pu, et al.
Publicado: (2021)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis
por: Fan, Tao, et al.
Publicado: (2021)

Cytokine Expression of Lung Bacterial Infection in Newly Diagnosed Adult Hematological Malignancies
por: Li, Zengzheng, et al.
Publicado: (2021)

Inducers, Attractors and Modulators of CD4(+) Treg Cells in Non-Small-Cell Lung Cancer
por: Xie, Mengxiao, et al.
Publicado: (2020)

Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non–small cell lung cancer
por: Aramini, Beatrice, et al.
Publicado: (2022)

Modulation of natural killer cell exhaustion in the lungs: the key components from lung microenvironment and lung tumor microenvironment
por: Zhang, Hongxia, et al.
Publicado: (2023)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients
por: Xiong, Anning, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vpuv5em55uargtqtocqtufc7e2